The Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. Stocks were essentially flat Tuesday after the S & P 500 and Nasdaq kicked the week off in the red. Higher Treasury yields are a wrinkle in Tuesday's action, making companies with higher dividend yields relatively less attractive.
Shares of Eli Lilly traded 1.3% higher Tuesday after the pharmaceutical giant launched single-dose vials of obesity drug Zepbound in the U.S. to boost supply. Fervent demand for the drug since its debut late last year has helped push Lilly's stock to incredible heights in 2024, up more than 60%. Still, shortages have been an issue. Lilly's long-term future remains bright, but Jim said our discipline requires us to take some off the table as the company nears a $1 trillion valuation.
Jim Cramer Investment Strategy Markets Breaking News: Markets Palo Alto Networks Inc Best Buy Co Inc Coterra Energy Inc Eli Lilly And Co S&P 500 Index NASDAQ Composite Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Selloff or Market Correction? Either Way, Here's What to Do NowStocks Analysis by Investing.com (Thomas Monteiro) covering: Eli Lilly and Company, Costco Wholesale Corp. Read Investing.com (Thomas Monteiro)'s latest article on Investing.com
Read more »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
1 Stock to Buy, 1 Stock to Sell This Week: Eli Lilly, Walt DisneyStocks Analysis by Investing.com (Jesse Cohen) covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, Caterpillar Inc. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »